Search Results for "Sunitinib"

12:37 EDT 20th August 2014 | BioPortfolio

Matching Channels

None

Matching News

Sunitinib or Everolimus First-Line for Kidney Cancer?

A phase 2 randomized comparator trial has found that first-line everolimus is not as effective as first-line sunitinib, and has a different toxicity profile. Medscape Medical News

Sunitinib malate (Sutent) for renal cell carcinoma – adjuvant therapy

Sunitinib malate (Sutent) is an oral small-molecule inhibitor with selectivity for platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1,...

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma.

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest...

Alternative sunitinib treatment schedules for mRCC may be worth the switch

Some patients with metastatic renal cell carcinoma who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse...

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

[News] Sunitinib still first-line therapy for metastatic renal cancer

Everolimus (an mTOR inhibitor) does not yield better results compared with sunitinib (a VEGFR tyrosine kinase inhibitor) as first-line therapy in patients with metastatic renal-cell carcinoma, new res...

Sunitinib re-challenge in advanced renal-cell carcinoma

Matching PubMed Articles

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction.

Sunitinib is an inhibitor of the multiple receptor tyrosine kinases (RTKs) for cancer therapy. Some sunitinib analogues could prevent neuronal death induced by various neurotoxins. However, the neurop...

Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.

Background: Fluoroquinolones are widely prescribed antibiotics. Ciprofloxacin is a well-known inhibitor of cytochrome P450 CYP3A4 and causes numerous drug interactions that are not found for levofloxa...

Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of suni...

Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis.

There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patien...

A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.

Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyp...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement